Evidence map›Paper›PMID 35315593›Full record

Observational studyCancer medicine2022

HTLV-1 Tax-specific memory cytotoxic T lymphocytes in long-term survivors of aggressive-type adult T-cell leukemia/lymphoma.

Tatsuro Jo, Kazuhiro Noguchi, Takahiro Sakai, Ritsuko Kubota-Koketsu, Sadaharu Irie, Masatoshi Matsuo, Jun Taguchi, Kuniko Abe, Kazuto Shigematsu

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Tatsuro JoDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.ORCID 0000-0001-5415-6228
Kazuhiro NoguchiDepartment of Laboratory, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Takahiro SakaiDepartment of Laboratory, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Ritsuko Kubota-KoketsuDepartment of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.ORCID 0000-0002-0623-038X
Sadaharu IrieDepartment of Pharmacy, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Masatoshi MatsuoDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Jun TaguchiDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Kuniko AbeDepartment of Pathology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Kazuto ShigematsuDepartment of Pathology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Japanese Red Cross Society, Japan · JPEkaterinburg Research Institute of Viral Infections · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAdult T-cell leukemia/lymphoma (ATLL) is a relatively refractory peripheral T-cell lymphoma caused by human T-cell lymphotropic virus type 1 (HTLV-1). The objective of this study was to investigate the characteristics of long-term survivors with ATLL.

methodsWe conducted an observational study of 75 aggressive-type ATLL patients. Flow cytometry was conducted to analyze HTLV-1 Tax-specific cytotoxic T-lymphocytes (CTLs) and T-cell receptor Vβ gene repertoire.

resultsWe first evaluated six long-term survivors among 37 patients who were newly diagnosed with ATLL and then treated with intensive chemotherapy without mogamulizumab, a monoclonal antibody for C-C chemokine receptor four antigen. Reversal of the CD4-to-CD8 ratio (CD4/CD8) in peripheral mononuclear cells was observed in all six patients. Three of these six patients showed reversed CD4/CD8 immediately after herpes virus infection. Four of these six patients who could be examined demonstrated long-term maintenance of HTLV-1 Tax-specific CTLs. We subsequently identified four long-term survivors among 38 patients who were newly diagnosed with ATLL and then treated with intensive chemotherapy plus mogamulizumab. All four patients showed reversed CD4/CD8, and three of the four patients contracted herpes virus infection during immunochemotherapy. Six of the total 10 patients were subjected to CTL analyses. Tax-specific CTLs were observed, and the CTLs that were almost entirely composed of memory CTLs in all patients were recorded. HTLV-1 provirus was also detected in all six patients.

conclusionsThese data suggest that Tax-specific memory CTLs probably, together with anticancer agents, eradicate ATLL cells and exhibit long-term preventive effects from relapse ATLL. Thus, the strong activation of cellular immunity, such as herpes virus infection, seems to be necessary to induce such a potent number of Tax-specific CTLs.

Indexed as

Antineoplastic AgentsHTLV-I InfectionsHuman T-lymphotropic virus 1Leukemia-Lymphoma, Adult T-CellLymphoma, T-Cell, PeripheralVirus DiseasesAdultGene Products, taxHumansSurvivorsT-Lymphocytes, CytotoxicAntineoplastic AgentsGene Products, taxadult T-cell leukemia/lymphomacytotoxic T-lymphocytesherpes virus infectionhuman T-cell lymphotropic virus type 1Tax

Identifiers

PMID35315593
PMCPMC9468428
OpenAlexW4220955175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.